Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 3
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Petrylak, D. P. Articles by Crawford, E. D. Search for Related Content PubMed Articles by Petrylak, D. P. Articles by Crawford, E. D.

Abstract

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)

New York Presbyterian Hospital, New York, NY; University of Washington, Seattle, WA; University of Michigan, Anne Arbor, MI; University of California Davis Cancer Center, Sacramento, CA; NASA Johnson Space Center, Houston, TX; Dana Farber Cancer Center, Boston, MA; Mayo Clinic, Rochester, MN; University of Arkansas, Little Rock, AR; University of California San Francisco, San Francisco, CA; University of Colorado, Denver, CO

3

Background: The median survival of AIPCA patients (pts) treated with M+P is 10–12 months. Phase I/II trials of AIPCA pts treated with D+E reported survivals of 20–23 months. SWOG 99–16 was designed to compare the survival D+E to M+P. Methods: 770 men with progressive AIPCA were randomized to either Arm 1) Dexamethasone 60 mg premedication; D=60 mg/m² day(D) 2, E= 280 mg PO D1–5 Q 21 D or Arm 2) M 12 mg/m² + P 5 mg PO BID q 21 D. Pts were dose escalated to 70 mg/m² in Arm 1 and 14 mg/m²in Arm 2 if no Grade(G) 3 or 4 toxicities were observed in cycle 1. Assuming 310 eligible pts in each arm, the study had 0.80 power to detect a 33% difference in survival. All p-values reported are two-sided. Results: Pt Characteristics: Eligible pts Arm 1:334; Arm 2 :332. Pretreatment characteristics were equally balanced for age, race, performance status, PSA and symptoms. Response and Survival: The median survival of men treated on Arm 1 was 18 months and Arm 2 was 15 months (logrank p=.008). The hazard ratio was 0.77 (95% confidence interval 0.64, 0.94). Arm 1 also demonstrated a superior median time to progression (6 months) compared to Arm 2 (3 months) logrank p<0.0001. The measurable disease response rates in Arm 1 and 2 were 17% and 10% (p=.30), respectively. Toxicity: G 3 or 4 toxicity was reported in 175 pts (54%) on Arm 1 and 109 pts (34%) on Arm 2, due to higher rates of gastrointestinal (63pts vs. 21pts) and cardiovascular (44pts vs 20pts) events on Arm 1. There was no significant difference in toxic deaths observed Arm 1 (n=7, 2%) vs. Arm 2 (n=4, 1%). Conclusions: The 23% improvement in survival in men treated with D+E supports its use as first line therapy for AIPCA. This is the first large randomized trial demonstrating a survival advantage in AIPCA.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis

Abstract presentation from the 2004 ASCO Annual Meeting